Cybin Shareholders Consider Rebranding to Helus Pharma and Board Expansion
Cybin Inc., operating as Helus Pharma, held a shareholder meeting on September 22, 2026, seeking approval for several key corporate changes. The company requested shareholders' consent to rebrand from Cybin Inc. to Helus Pharma Inc., set the board size at eight members, and appoint Zeifmans LLP as auditor. All proposals required two-thirds majority support but no results were disclosed during the meeting. The proposed name change aligns with its ongoing business operations under the 'Helus Pharma' brand. Shareholders also voted on electing eight director nominees, including co-founder Eric So and CEO Michael Halstead. The company emphasized that voting details would be published after the event but did not announce preliminary results during the meeting. The rebranding effort reflects a strategic shift in corporate identity as Cybin continues to focus on its pharmaceutical initiatives under Helus Pharma.
Tickers: $HELP